4A3 Stock Chart & Stats
€7.90
€0.33(4.29%)
At close: 4:00 PM EDT
€7.90
€0.33(4.29%)
Day’s Range― - ―
52-Week Range€4.30 - €10.15
Previous CloseN/A
Volume346.00
Average Volume (3M)2.09K
Market Cap
€1.01B
Enterprise Value€819.68
Total Cash (Recent Filing)€454.04M
Total Debt (Recent Filing)€15.10M
Price to Earnings (P/E)―
Beta0.57
Next Earnings
Aug 19, 2026EPS Estimate
-0.42Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.71
Shares Outstanding134,096,570
10 Day Avg. Volume551
30 Day Avg. Volume2,092
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)2.26
Price to Sales (P/S)22.65
P/FCF Ratio-6.21
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€17.06Price Target Upside115.94% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering6
EPS Forecast (FY)-1.5
Revenue Forecast (FY)€33.31M
Bulls Say, Bears Say
Bulls Say
Proprietary Antigen Discovery And TCR Engineering PlatformImmatics’ integrated antigen discovery and TCR engineering platform is a durable competitive asset that underpins multiple programs and partnerships. Platform ownership supports repeatable program generation, raises barriers to entry, and sustains long‑term partner interest and licensing potential beyond individual trials.
Compelling Phase 1 Clinical Data For Lead ProgramsRobust Phase 1 anti‑tumor activity and durable responses for IMA203CD8 and positive tolerability for IMA401 materially de‑risk core programs. Clinically meaningful efficacy in heavily pretreated patients supports Phase 2 advancement, broadens addressable indications, and strengthens long‑term partnering and commercialization prospects.
Low Leverage And Balance Sheet FlexibilityVery low debt-to-equity gives Immatics structural financial flexibility to fund R&D, pursue collaborations, and manage timing of clinical spend without immediate insolvency pressure. Combined with shareholder approvals for repurchase/incentive plans, this supports measured capital allocation over the medium term.
Bears Say
Large Negative Operating And Free Cash FlowSustained, sizable cash outflows driven by clinical and platform R&D create persistent funding needs. Over months to a few years this raises refinancing and dilution risk, limits ability to scale operations organically, and forces reliance on partnerships or equity markets to bridge development milestones.
Declining And Volatile Collaboration RevenueHeavy dependence on collaboration receipts makes revenue timing unpredictable; recent steep drop while R&D spend rose tightens cash runway. Variability in partner payments and milestone timing complicates planning and elevates risk that revenue shortfalls outpace available financing.
Very Large Losses And Negative Returns On EquityDeep negative margins and materially negative ROE indicate the business currently destroys capital rather than generates returns. If sustained, losses erode equity, constrain reinvestment, and increase dependence on external financing, creating long‑term dilution and governance pressure.
Immatics News
4A3 FAQ
What was Immatics’s price range in the past 12 months?
Immatics lowest stock price was €4.30 and its highest was €10.15 in the past 12 months.
What is Immatics’s market cap?
Immatics’s market cap is €1.01B.
When is Immatics’s upcoming earnings report date?
Immatics’s upcoming earnings report date is Aug 19, 2026 which is in 14 days.
How were Immatics’s earnings last quarter?
Immatics released its earnings results on May 12, 2026. The company reported -€0.43 earnings per share for the quarter, missing the consensus estimate of -€0.396 by -€0.034.
Is Immatics overvalued?
According to Wall Street analysts Immatics’s price is currently Undervalued.
Does Immatics pay dividends?
Immatics does not currently pay dividends.
What is Immatics’s EPS estimate?
Immatics’s EPS estimate is -0.42.
How many shares outstanding does Immatics have?
Immatics has 134,096,570 shares outstanding.
What happened to Immatics’s price movement after its last earnings report?
Immatics reported an EPS of -€0.43 in its last earnings report, missing expectations of -€0.396. Following the earnings report the stock price went down -3.1%.
Which hedge fund is a major shareholder of Immatics?
Currently, no hedge funds are holding shares in DE:4A3
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Immatics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
€17.06 (115.94% Upside)
€17.06 (115.94% Upside)
Blogger Sentiment
Bullish
DE:4A3 Sentiment 100%
Sector Average 65%
Sector Average 65%
Technicals
SMA
Negative
20 days / 200 days
Momentum
40.77%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-9.70%
Trailing 12-Months
Company Description
Immatics
Immatics N.V. is a clinical-stage biopharmaceutical firm dedicated to discovering and advancing T-cell receptor (TCR) based immunotherapies aimed at combating cancer, primarily within the United States. Its therapeutic strategy centers on targeted immunotherapies for solid tumors, utilizing two distinct approaches: adoptive cell therapies (ACT) and antibody-like TCR Bispecifics. The company's ACTengine™ portfolio features several candidates in Phase I clinical trials. These include IMA201, designed to recognize melanoma-associated antigens 4 or 8 in solid tumor patients; IMA202, which targets melanoma-associated antigen 1 across various solid tumor types, such as squamous non-small cell lung carcinoma and hepatocellular carcinoma; and IMA203, aimed at preferentially expressed antigen in melanoma in adult patients with recurrent or treatment-resistant solid tumors. Additionally, IMA204, currently in preclinical stages, focuses on targeting tumor stroma cells. In its preclinical TCR Bispecifics pipeline, Immatics is advancing IMA401, which targets cancer testis antigens for solid tumor indications, and IMA402, also under investigation for solid tumor therapies. Other programs include IMA101 for cancer treatment and IMA301, an allogeneic cellular therapy candidate. Immatics has established strategic partnerships to bolster its development efforts. These include collaborations with GlaxoSmithKline Intellectual Property Development Limited for novel adoptive cell therapies across various cancer indications; MD Anderson Cancer Center for multiple T-cell and TCR-based adoptive cellular therapies; Celgene Switzerland LLC for additional novel adoptive cell therapies; and Genmab A/S to develop T-cell engaging bispecific immunotherapies for diverse cancer indications. The company's headquarters are situated in Tübingen, Germany.
4A3 Stock 12 Month Forecast
Average Price Target
€17.06
▲(115.94% Upside)